Connect with us

Health

New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape

The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…

Published

on

Article feature image
ADVERTISEMENT

Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Researchers demonstrate an alternative way to produce highly detailed images of the brain – News-Medical.Net
Article feature image
Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics – News-Medical.Net